Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation

Haematologica. 2020 Nov 1;105(11):2664-2666. doi: 10.3324/haematol.2019.242529.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents, Immunological* / adverse effects
  • Hodgkin Disease* / drug therapy
  • Humans
  • Programmed Cell Death 1 Receptor

Substances

  • Antineoplastic Agents, Immunological
  • Programmed Cell Death 1 Receptor